Shares in US biotech Pieris Pharmaceuticals (Nasdaq: PIRS) rocketed by nearly 50% in three hours of trading on Tuesday on news of a multi-program research collaboration and license agreement with the Roche (ROG: SIX) subsidiary Genentech.
The deal will see the companies link up to discover, develop and commercialize locally delivered respiratory and ophthalmology therapies that leverage Pieris' proprietary Anticalin technology.
"We look forward to working closely with Genentech on the development of new inhaled and ophthalmological treatments based on the Anticalin platform"Their research collaboration will enable Pieris to combine its robust discovery engine with Genentech's targets, as well as its pre-clinical and clinical development expertise, to create therapies for the treatment of respiratory and ophthalmological diseases. These two focus areas of the collaboration are uniquely suited to the advantages offered by the small size of Anticalin proteins when delivered locally.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze